Want to Go Far, Go Together (4.21.2023)

Save

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Sex-Specific Differences in Psoriatic Arthritis

Save

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.

Renal Function Safe With Pegloticase-MTX Combo for Gout

Save

For patients with uncontrolled gout, estimated glomerular filtration rate (eGFR) remained stable with combination pegloticase (Krystexxa) and methotrexate treatment, researchers reported.

Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis

Save

Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

The Match Game (4.14.2023)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Pain and Opioid Updates

Save

Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids.

MMWR April 14, 2023

RA Patients on Biologics and tsDMARDs are still High Risk

Save

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis

Save

A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.

Clinical Profile of RA-associated Interstitial Lung Disease

Save

A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.

Industry Payments to Rheumatologists Dropped During COVID

Save

Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.

“You Can Have it All” (4.7.2023)

Save

Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

Save

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.